Stay updated on Belantamab vs Bortezomib in MM Clinical Trial
Sign up to get notified when there's something new on the Belantamab vs Bortezomib in MM Clinical Trial page.
Latest updates to the Belantamab vs Bortezomib in MM Clinical Trial page
- Check5 days agoChange DetectedChanges appear limited to UI/layout tweaks and do not affect core study content such as arms, endpoints, enrollment, or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%
- Check12 days agoNo Change Detected
- Check26 days agoChange DetectedAdded new MedlinePlus Genetics topic on Multiple myeloma, expanding core content related to genetics of a specific disease.SummaryDifference0.1%
- Check34 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%
- Check41 days agoChange DetectedTerminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and version bumped from v3.0.2 to v3.1.0.SummaryDifference0.1%
- Check48 days agoChange DetectedAdded a new research citation (DREAMM-8 study) to the page; no deletions observed.SummaryDifference0.9%
- Check55 days agoChange DetectedPage updated to v3.0.2; removed the ‘MedlinePlus Genetics related topics: Multiple myeloma’ entry and the ‘Back to Top’ link.SummaryDifference0.2%
Stay in the know with updates to Belantamab vs Bortezomib in MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Belantamab vs Bortezomib in MM Clinical Trial page.